



Antibiotic resistance surveillance systems: A review

Ousmane Oumou Diallo, Sophie Alexandra Baron, Cedric Abat, Philippe Colson, Herve Chaudet, Jean-Marc Rolain

► To cite this version:

Ousmane Oumou Diallo, Sophie Alexandra Baron, Cedric Abat, Philippe Colson, Herve Chaudet, et al.. Antibiotic resistance surveillance systems: A review. Journal of Global Antimicrobial Resistance, 2020, 23, pp.430-438. 10.1016/j.jgar.2020.10.009 . hal-03149229

HAL Id: hal-03149229

<https://amu.hal.science/hal-03149229>

Submitted on 15 Dec 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

TITLE: Antibiotic Resistance Surveillance Systems: A Review

Authors list : Ousmane Oumou DIALLO^{1,2}, Sophie Alexandra BARON^{1,2}, Cédric ABAT¹,
Philippe COLSON^{1,2}, Hervé CHAUDET^{1,3}, and Jean-Marc ROLAIN^{1,2*}

Affiliations: ¹ IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France; ² Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Microbes Evolution Phylogeny and Infections (MEPHI), 19-21 boulevard Jean Moulin, 13005 Marseille, France; ³ Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Vecteurs – Infections Tropicales et Méditerranéennes (VITROME), 19-21 boulevard Jean Moulin, 13005 Marseille, France

*** Corresponding author :** Jean-Marc ROLAIN, Aix Marseille Univ, IRD, APMH, MEPHI, IHU-Méditerranée Infection, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille CEDEX 05, France. Phone: (33) 4 91 32 43 75. Email: jean-marc.rolain@univ-amu.fr

Word count:

abstract: 249<250

text: 3 993<5000

ABSTRACT

Objective:

Epidemiological surveillance is one critical approach to estimate and fight against the burden of antibiotic resistance (AR). Herein, we summarize the characteristics of surveillance systems devoted to the surveillance of AR worldwide and published in literature.

Methods:

We performed a systematic review of the literature available on PubMed from January 2007 to July 2019 (12.5 years). The key words ("surveillance system" OR "laboratory-based surveillance" OR "syndromic surveillance" OR "sentinel surveillance" OR "integrated surveillance" OR "population-based surveillance") AND ("antibiotic resistance" OR "antimicrobial resistance") were used. This research was completed with antibiotic resistance monitoring systems available on websites.

Results:

We identified 71 antibiotic resistance surveillance systems described by 90 publications from 35 countries: 65 (91.5%) national surveillance systems and 6 (8.5%) multinational. Two regions accounted for 73% of admissions: European region (37; 52.9%), and region of the Americas (14; 20.2%). Fifty-three focused on AR surveillance in human, 12 studied both humans and animals, and 3 focused only on animals.

The two most common bacterial species reported were *Staphylococcus aureus* (42; 59.2%) and *Escherichia coli* (39; 54.9%). Twenty out of 71 (28.2%) antibiotic resistance surveillance systems used prevalence as indicator, 3 (4.2%) used incidence and 7 (9.9%) both. Methicillin-resistant *S. aureus*, vancomycin resistance for *Enterococcus spp*, *S. aureus* and *Streptococcus pneumoniae*, penicillin-resistant-*S. pneumoniae*, Extended Spectrum Beta-Lactamase and carbapenem resistance for *E. coli* and *Klebsiella pneumoniae* were monitored.

Conclusion:

57 Our results showed heterogeneous surveillance systems. A "one health approach" is needed to
58 monitor antibiotic resistance, with reference to the WHO Global Action Plan.

59 **Keywords:** Antibiotic resistance, surveillance systems, Clinical microbiology laboratories

60

INTRODUCTION

The 20th century was considered as the “golden age” of antibiotics, as they have been extensively used in humans and animals [1,2]. These antibiotics have contributed to a dramatic decrease in morbidity and mortality due to infectious diseases worldwide [3–6]. This antibiotic consumption has continued to increase in the 21st century, probably due to better access of low- and middle-income countries to antibiotics. In addition global antibiotic consumption increased by 65% between 2000 and 2015 worldwide, which is inversely correlated with the decrease in deaths from infectious diseases [4,7].

However, the massive use of antibiotics also led to the selection of resistant bacterial strains [7,8]. A study in the USA has a positive correlation between the use of macrolides and the proportion of resistance in *Streptococcus pneumoniae* isolates (Spearman's ρ =64%, IC 95% 41% - 80% [9]. Increasing AR complicates infection management by limiting the number of active antibiotics available and results in difficult-to-treat cases of infections and situations where recommended and available antibiotics are no longer active. This situation has led some investigators to design mathematical models predicting several million deaths, due to bacterial resistance-[10–12]. The European Center for Disease Prevention and Control (ECDC) estimated the number of extra deaths due to multidrug resistant (MDR) to be 25,000 humans deaths per year in the European countries in 2009 [12]. In 2013, the Center for Disease Control and Prevention (CDC) published a report estimating the number of extra deaths due to AR to reach 23 000 people per year in the USA [13]. The Burden study estimated that MDR bacteria were responsible for 12 500 extra deaths every year in France [14]. Finally, in 2016, the team of Lord Jim O’Neill published a report estimating that antimicrobial resistance could be responsible for 10 million deaths per year globally, by 2050 [11].

85 These reports have considerable caveats as they extrapolate through mathematical models on
86 estimates and do not use objective epidemiological counts [8,10,15,16]. Therefore, one
87 solution to collect antimicrobial resistance data is to implement an antibiotic resistance (AR)
88 surveillance system [17]. Moreover, AR highly varies from one region to another according to
89 the incidence and prevalence of infectious diseases, the panels of antibiotics used and
90 antibiotic susceptibility tests performed. The future AR surveillance system implemented
91 would ensure should take these disparities into account to propose an indicator (Incidence or
92 Prevalence), which antibiotics are used and which tests for used. AR surveillance systems are
93 defined as “a structured and systematic procedure to measure the prevalence or incidence of
94 antibiotic resistance through continuous or periodical surveillance performed with a defined
95 methodology and with specified indicators” [18]. The data collected by such systems can then
96 be used to design empirical therapy and implementation of local and national antibiotic
97 treatment guidelines [19]. Besides, AR can also be detected in animals and in the environment
98 [20]. Several studies have already shown, for example, that people in contact with livestock,
99 especially calves and pigs, have an increased risk of MRSA [21]. It is in this context that the
100 WHO has implemented the concept of “one health”. The latter notably advocates surveillance
101 of AR in humans, in animals, and in the environment with a multi-sectoral partnership
102 between different research teams [22]. AR surveillance systems can differ considerably
103 regarding their methods and exhaustivity, which can limit the interpretation, comparison and
104 extrapolation of their data. These surveillance systems are not uniformly implemented
105 throughout the world. Some authors have already listed the different surveillance systems in
106 Europe [23] and in low and middle-income countries [24]. However, there have been no
107 studies of AR surveillance systems listed worldwide. The purpose of this review is to identify
108 and to detail the different AR surveillance systems in the world. To this end, we will first
109 inventory all different AR surveillance systems in the world, then identify the different

bacterial species monitored, as well as the critical phenotypes, and finally determine the incidence and/or prevalence of the major phenotypes by surveillance system.

MATERIAL AND METHODS:

1- Systematic review of the literature

We performed a systematic review of the literature available on PubMed to search for publications describing AR surveillance systems collecting and analyzing incidence and/or prevalence data on AR. To do so, we used the following words/terms “surveillance system”, “laboratory-based surveillance”, “syndromic surveillance”, “sentinel surveillance”, “integrated surveillance”, “population-based surveillance”, “antibiotic resistance” and “antimicrobial resistance”. This research was conducted from January 2007 and July 2019 and papers written in English and French were included.

The Mendeley references manager was used to de-duplicated the search results. This PubMed search was completed by adding AR surveillance systems included reports published by learned societies or others not indexed in PubMed. References from relevant articles were also screened. Articles that do not mention a surveillance system, a surveillance program or a surveillance study were excluded after reading their abstracts. After reading the articles, only articles describing a surveillance system or a surveillance program in humans, animals and / or environment were retained.

Studies were included if they reported a surveillance system and provided incidence and/or prevalence data for at least a 1-year period since 2007.

The data collected included: surveillance systems, bacterial species, antimicrobials, geographical areas, antibiotic resistance patterns, system updates, incidence and/or prevalence.

2- Definition

An AR surveillance system was considered to be up to date when the system complied with the publication of reports (weekly, monthly or annual) that it had prepared or when the system published at least one report in the last 3 years. As example, we considered that ISIS-AR ('Infectious Diseases Surveillance Information System for Antimicrobial Resistance') to be up to date because the last report was dated 2017 and so was the EARS-NET network, while the last report was dated 2017.

We used the definition given by each system for a given AR phenotype without a re-interpretation of the antibiotic susceptibility test(s) when available. For the prevalence and/or incidence of AR, we simply used data from the different reports without modification.

Inclusion criteria: A surveillance system having a structured and systematic procedure for analyzing prevalence and/or incidence data, reporting data periodically or continuously, or having reported data at least a 1-year period since 2007.

Exclusion criteria: We excluded all articles referring to case-control studies, prevalence studies and cross-sectional study.

RESULTS:

1. Literature search

Our literature search enabled us to firstly identify 299 articles in PubMed. Of these articles, 90 (30.1%) met our inclusion criteria (Fig 1). These articles ultimately allowed us to clearly identify 71 AR surveillance systems. More details about these systems are summarized on Supplementary Table 1.

2. Localisation

Seventy-one AR surveillance systems from 35 countries were described, of which 65 (91.5%) were national surveillance systems and 6 (8.5%) were multinational (Table S.1). Two regions accounted for approximately 73% of admissions, European (37; 52.9%) and region of the

Americas (14; 20.2%). Other regions were: Western pacific region (12; 17.4%), African region (3; 4.3%), South East Asia region (3; 4.2%) and Eastern Mediterranean region (2; 2.8%). The most represented country was the USA with 7 out of 71 (9.9%) AR surveillance systems. 26 out of 71 (36.6%) surveillance systems were considered up to date; 45 out of 71 (63.4%) surveillance systems were not. 19 out of 71 (26.8%) are monitoring systems for which no report was found; 26 out of 71 (36.6%) are monitoring systems with at least one report found. 25 out of 26 (96.2%) had published at least one report in the past five years. Three out of 26 (11.5%) of them are real-time monitoring systems and have an alarm detection system for critical phenotypes (Marseille Antibiotic Resistance Surveillance System (MARSS), EPIdemiological Surveillance and Alert Based on MICrobiological Data (EPIMIC) and Swedish Surveillance of Antimicrobial Resistance (SVEBAR)). Nine out of 71 (12.7%) have an interactive database in which one could collect information on the percentage of resistance of specific antibiotics and/or phenotypes for a given period. Thirty out of 52 (57.7%) reports are written in English, 14 out of 52 (26.9%) in a local native language, 8 out of 52 (15.4%) in both English and local native language.

3. Bacterial species and phenotypes monitored

Sixty-three of 71 (88.7%) surveillance systems monitor 48 bacterial species and/or genera, and the others (11.3%) did not provide information on the bacterial species and/or genera being monitored. Table 1 shows the main species and/or genera monitored by the different AR surveillance systems. The most common bacterial species and/or genera reported were: *Staphylococcus aureus* (42; 59.2%), *Escherichia coli* (39; 54.9%), *S. pneumoniae* (30; 42.3%), *Pseudomonas aeruginosa* (26; 36.6%), *Klebsiella pneumoniae* (24; 33.8%), *Enterococcus faecalis* (19; 26.8%), *Salmonella* spp. (18; 25.4%), *Enterococcus faecium* (17; 23.9%), *Haemophilus influenzae* (15; 21.1%), and *Neisseria gonorrhoeae* (14; 19.7%). The surveillance system that had the greatest number of bacterial species and / or genus monitored

was ANRESIS (Swiss Antibiotic Resistance Surveillance database) with 26 species and / or genus. Eleven of 71 (15.5%) surveillance systems monitored one single bacterial species; the most common bacterium monitored was *N. gonorrhoeae* (3; 27.3%), followed by *Helicobacter pylori* (2; 18.2%). One of 11 (9.1%) is up to date (National TB surveillance system (NTSS)), 2 of 11 (18.2%) provided at least a 5-year report (European Gonococcal Surveillance Program (EURO-GASP), Gonococcal Isolate Surveillance Project (GISP)), and the remaining 9 (81.8%) have no reports found. Of these 71 surveillance systems, only 38 (54.3%) simultaneously monitored a critical antibiotic resistance phenotype. The most frequently monitored critical phenotypes were: methicillin-resistant *S. aureus* (MRSA) (30; 42.3%), carbapenem-resistant *Enterobacteriaceae* (19; 26.8%), vancomycin-resistant *Enterococci* (18; 25.4%), Extended Spectrum Beta-Lactamase for *Enterobacteriaceae* (16; 22.5%), *Staphylococcus* resistant to vancomycin (6; 8.5%) and streptococci resistant to penicillin (5; 7.0%).

4. Human vs Animals

Among the 71 surveillance systems, 53 (74.64%) were exclusively from human isolates, 12 (16.90 %) targeted both humans and animals, and 3 (4.22%) focused on the surveillance of AR in animals (Figure 1). The latter 6 surveillance systems monitored bacteria of zoonotic origin, including *Campylobacter* spp., *Salmonella* spp. and commensal bacteria (*E. coli*) according to the European Union (EU) legislation on monitoring and reporting of AR in zoonotic and commensal bacteria (2013/652/EU). As an example, the surveillance of AR and Antibiotic Usage in Animals in the Netherlands (MARAN) was launched in 2008 for the surveillance of AR data routinely produced by a network of 42 medical microbiological laboratories and one veterinary laboratory for the animal data. The medical microbiological laboratories were distributed as follows: four of these laboratories exclusively serve a university hospital, two exclusively serve general practitioner (GP) practices, obstetrician

practices, long-term care facilities and public health facilities, 36 serve both general hospitals and GP practices. [19]. *Campylobacter* spp. and *Salmonella* spp. isolates were sampled from food animals, meat and from humans with clinical enteral infections/acute gastroenteritis. The results of the antibiotic susceptibility testing (AST) were collected monthly from a laboratory information system that automatically generates reports. The data showed that there was no carbapenemase in the different *Salmonella* spp strains tested in 2017, whereas colistin resistance gene *mcr-1* was identified at low-level in *E. coli* from livestock (1.2%) and at higher levels in retail meat from chicken (7.7%), but not in *Salmonella*.

The Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM) was launched in 1999. The purpose of the JVARM antibiotic-resistance surveillance system is to monitor the susceptibility of foodborne pathogenic (*Campylobacter jejuni*, *Campylobacter coli* and *Salmonella* spp) and commensal bacteria (*E. coli*, *E. faecium* and *Enterococcus faecalis*) from production animals to antimicrobials agents. Data from the JVARM showed a slight increase of the prevalence of *mcr-1* in *E.coli* over the years [25].

5. Incidence and/or Prevalence of critical phenotypes

Twenty out of 71 (28.2%) antibiotic resistance surveillance systems for which data are available use prevalence as an indicator whereas 3 (4.2%) use incidence, and 7 (9.9%) use both prevalence and incidence. Table 2 shows the raw prevalence and/or incidence of the main phenotypes of the different antibiotic resistance surveillance systems. For Gram positive bacteria, only MRSA, vancomycin resistance for *Enterococcus spp*, *S. aureus*, *S. pneumoniae* and penicillin resistant for *S. pneumoniae* were found, and for Gram negative bacteria, Extended-spectrum-Beta-Lactamases (ESBL) for *E. coli*, *K. pneumoniae*, carbapenem resistant for *E. coli* and *K. pneumoniae* were monitored.

For MRSA, the prevalence of resistance was <5% in 4 out of 20 (20%) antibiotic resistance surveillance systems in the Netherlands (ISIS-AR), United Kingdom (BSAC), Finland (FIRE)

and Sweden (SVEBAR), 5-15% in 6 out of 20 (30%) antibiotic resistance surveillance systems in Switzerland (ANRESIS), Australia (AURA), EARS-NET, Bulgaria (BulSTAR), Croatia (ISKRA), Germany (ARMIN) and Japan (JANIS), >15% in 8 out of 20 (40%) antibiotic resistance surveillance systems in South Korea (KOR-GLASS), Argentina (WHONET-Argentina), Germany (SARI), Greece (WHONET-GREECE), France (ONERBA), CAESAR, Thailand (NARST), and Philippines (ARSP). The prevalence of carbapenem resistance was less than 1% in the majority of surveillance systems except for Thailand antibiotic resistance surveillance system (NARST) for *E. coli*, likewise for *K. pneumoniae*, the prevalence was <5% in 17 out of 24 (70.8%) , > 5% in 5 antibiotic resistance surveillance systems (Ears-net,), in Argentina (WHONET-Argentina), Thailand (NARST), Greece (WHONET-GREECE), CAESAR and Philippine (ARSP).

6. Advantages and disadvantages of different antibiotic resistance surveillance systems

The data collected by the various AR surveillance systems have the advantage of providing information on the actual burden of resistance at the local, national and international levels. For instance, in Marseille, the antibiotic resistance surveillance system (MARSS) has shown between 2001 and 2016 an increase of resistance to third-generation cephalosporins for *E. coli* invasive strains (0% vs 17.8%; $p < 10^{-5}$) and *K. pneumoniae* (8% vs 35.4%; $p = 0.001$), along with a decrease of MRSA strains (31% vs 19.8%; $p = 0.006$) [26]. In Europe, according to the 2017 EARST-NET report, the EU and EEA weighted average percentage of MRSA has decreased (19.6% in 2014 to 16.9% in 2017) [27]. In the Netherlands, the antibiotic resistance surveillance system (ISIS-AR) has shown that the level of resistance to colistin in *E. coli* and *K. pneumoniae* remained stable over the last 5 years [19].

Different AR surveillance systems have different objectives, which imply a data collection methodology tailored to each objective. As example, the antibiotic resistance Surveillance

System (DANMAP) collects data on the consumption and AR of indicator bacteria, zoonotic bacteria and pathogenic bacteria of animal, food and human origin, to determine the association between consumption and resistance development, and modeling the transmission of AR to humans. The system ISIS-AR collects data on antibiograms and some epidemiological data in humans and animals.

AR surveillance systems do not use the same rule of interpretation, which makes comparison between them very difficult. In the USA, NARMS uses the Clinical and Laboratory Standards Institute (CLSI) interpretation rule and in Europe, EARS-NET uses the European Committee for Antimicrobial Susceptibility Testing (EUCAST) criteria. It has been shown that the change in interpretation tools from CLSI to EUCAST has increased the number of strains classified as multidrug-resistant (MDR) including *K. pneumoniae* (2.2%), *Enterobacter cloacae* (1.1%), *P. aeruginosa* (0.7%) and *E. coli* (0.4%) [28]. For some bacteria-antibiotic couple, such as *E. coli*-ciprofloxacin and *K. pneumoniae*, the agreement between CLSI and EUCAST was 77.8% and 61.5% respectively [28]. Patient clinical data are unavailable in most antibiotic resistance surveillance systems, and genotyping is almost absent in these systems. This is due on the one hand to the regulatory provisions of countries such as in European countries where privacy laws are increasingly defended. On the other hand, to obtain clinical information, it will be necessary to have a unique identifier for each patient, which is difficult for countries that do not have a medical information system in place.

DISCUSSION

We performed a review of antibiotic resistance systems available worldwide. In this review we attempted to be comprehensive, encompassing all AR surveillance systems in the world. It also provides information on the phenotypes and different bacterial species monitored. It

284 shows the value of the "one health" concept and describes the future surveillance system for
285 AR.

286 The seventy AR surveillance systems were mainly human surveillance systems. The bacterial
287 species monitored were those responsible for the main bacterial infections in humans (*S.*
288 *aureus*, *E. coli*, *K. pneumoniae*, *S. pneumoniae*, *H. influenzae*). However, few systems
289 monitor AR in animals (*Salmonella spp*, *Campylobacter spp*) and commensal (*E. coli*, *E.*
290 *faecium* and *E. faecalis*) bacterial species.

291 The data used by the different AR surveillance systems are very heterogeneous and difficult
292 to compare (selection of bacterial species to be monitored, choice of antibiotics, monitored
293 phenotypes, methods of antibiotic susceptibility determination, the fact that they use different
294 antibiotics to define the same phenotype is an example of heterogeneity). There are several
295 scenarios; some AR surveillance systems use cefoxitin, oxacillin and/or flucloxacillin to
296 define MRSA. The Dutch national antibiotic resistance surveillance system (ISIS-AR)
297 includes cefoxitin results to define MRSA and if this antibiotic is not available, oxacillin
298 and/or flucloxacillin are used [19]. The Canadian antibiotic resistance Surveillance System
299 (CARSS), however, uses methicillin, oxacillin and cefazolin to define this same phenotype
300 [29]. Another obstacle to compare data between different AR surveillance systems is the use
301 of different epidemiological indicators between systems and sometimes even within the same
302 AR surveillance system. Thus, the European network (EARS-NET), uses prevalence as an
303 indicator to estimate the burden of AR per pathogen [30,31], while the CNISP (Canadian
304 Nosocomial Infection Surveillance Program) antibiotic uses incidence [29]. The DANMAP
305 uses both prevalence and incidence in estimating the burden of bacterial AR [32]. These
306 limitations are related to a lack of international coordination, inadequate standardization of
307 epidemiological definitions, samples and data collected, culture media used, microbiological
308 testing methods, and publication of reports years after data collection [23]. The diversity of

309 sources of bacterial isolates considered is another limitation of some AR surveillance systems.
310 Some surveillance systems focus only on invasive clinical specimens (blood and
311 cerebrospinal fluid) while others include all types of clinical samples. This is a crucial aspect
312 in estimating the burden of AR. Including all strains without regarding the sample nature
313 allow to have a global snapshot of antibiotic resistance prevalence, even if it is just carriage.
314 Having this information still give the possibility to make further analyses such as the
315 prevalence of AR in invasive samples and allow to evaluate relation between AR carriage and
316 infections. Focusing only on invasive samples could give a better idea of the impact of AR on
317 mortality but the link between bacteria isolated in samples, even invasive ones, and mortality
318 remains difficult to establish.

319 Therefore, a system collecting only blood cultures at a small sample size can hardly be
320 compared to a system that collects all types of samples. The simple fact of considering only
321 samples from invasive specimens could bias the weight estimate of AR, as De Kraker et al.
322 have shown [16]. For example, in the various reports estimating mortality due to antibiotic
323 resistance in Europe, only invasive samples are available; to obtain resistance in the other
324 samples, a ratio has been applied, which has the effect of biasing the weight of resistance.

325 The other aspect that should be considered is the coverage by the antibiotic resistance
326 surveillance system of the different laboratories and hospitals at a local, national, and global
327 level. As an example, EARS-NET (European Antibiotic Resistance Surveillance Network)
328 covers only tertiary hospitals in different countries and generalizes the burden of AR for
329 specific pathogens. The French disease burden study estimated that mortality due to resistance
330 in France was 12 500 deaths, but covered only 18% of French laboratories, and that they had
331 only invasive samples, the others were obtained by applying ratios from the literature
332 [8,14,16].

Although most of the AR surveillance systems listed in this review publish reports, the majority do so with a time frame of at least one year, which should be corrected by putting the data online in real-time. Thus, the publication of reports with real-time data makes it possible to update knowledge on emerging resistance events and mechanisms and detect an epidemic [19,23]. In addition, some AR surveillance systems, such as the Danish Integrated Antimicrobial Resistance Monitoring and Research Program (DANMAP) combine phenotypic identification with genotypic identification to identify *mecA* or even *mecC* genes in MRSA strains using whole genome sequencing (WGS) [32]. EUCAST members recommend to associate phenotypic surveillance with WGS since 2016 as a routine tool in clinical microbiology [33]. This method is as accurate to predict AR phenotype as phenotypic tests in *S. aureus* [34,35], *E. coli*, *K. pneumoniae* [36], *Salmonella* [37] and *Mycobacterium tuberculosis* [35,38]. The overall concordance rate was 90% between phenotypic tests and WGS according to the bacteria [33]. This tool is particularly useful in case of infections caused by slow-growing bacteria, such as Mycobacteria as it is faster than culture and allows informed and timely clinical decisions about antibiotic treatment strategies in patients [39]. Several recommendations suggested the implementation of surveillance of AR and antibiotic consumption in humans, animals and the environment [40].

In the light of our results, we find that no current system for monitoring AR takes into account the concept of “one health”, because of the absence of the environment component, the fauna in the data collected, but also because most current AR surveillance systems precede the concept of “one health” [40].

The fact that bacterial strains of animal or related origin have been identified in humans without direct exposure to animals, by linking them to food consumption and/or food handling, confirms the need for greater integration between human and animal surveillance systems [41]. For example, it has already been demonstrated by sequencing the entire genome

that MRSA in cattle has evolved from MRSA in humans [42]. Voss et al have also demonstrated that farm animals frequently transmit MRSA of animal origin to exposed humans [21]. The concept of “one health” recommends monitoring AR in humans, animals and the environment with multisectoral teams and international collaboration between different AR surveillance systems (or networks) [43]. It is in this same context that the WHO in its global plan of action against AR advocates a reinforcement of knowledge from the precise data from the surveillance. It would allow to deepen the knowledge on the real weight of the AR, its prevalence, incidence and geographical disparities among others, but also to optimize the use of antibiotics in human and animal health [44]. In addition, these data would allow us to know the actual number of deaths due to antibiotic resistance, which is currently being done in Marseille [8,10] .

The application of molecular techniques allows the detection and recognition of epidemic clones of resistant bacteria [45,46]. The integration of molecular technique could facilitate the detection of resistance mechanisms such as colistin [20]. Unfortunately, most current surveillance systems do not monitor colistin resistance while this antibiotic is a resort for the treatment of Gram-negative bacterial infections resistant to carbapenems. Thus, new mechanisms of colistin resistance have emerged in recent years around the world [20].

PERSPECTIVES AND FUTURE ACTIONS

Current computer systems and networks collect, analyze and transmit data at a large scale as we entered the period of big data. This should lead to collect, homogenize, analyze and report data at the broadest scale on the basis of true counts/measurements, rather than to lose ourselves in estimates, extrapolation and models. It is absolutely necessary to involve the various actors in the surveillance of antibiotic resistance (doctors, epidemiologists, veterinary surgeons, pharmacists) in the framework of "one health", in order to set up effective systems adapted to the current reality (Figure 2). Indeed, an ideal surveillance system would be a

system that combines from various sources/laboratories data from humans, animals and environments, analyzes the results of antibiotic susceptibility tests phenotypically, and combines molecular analysis by WGS to determine the distribution of high-risk clones and resistance mechanisms. These analyses must generate data available in the freely accessible public domain and export them in a standardized data exchange format. These antibiotic resistance surveillance systems must be scalable and extensible, reports must be available. In addition, given the disparity between the different methods of analysis and antibiotics tested, it is clearly identified that there is an urgent need to harmonize AST (Antibiotic Susceptibility Testing) techniques, to have minimal inhibitory concentration (MIC) for antibiotics to homogenize interpretations, and merge these collected data with a register of deaths due to AR. In the future, the various surveillance systems should have, in addition to microbiological data, demographic data and clinical data to facilitate understanding of the phenomenon of AR. This data, once collected, would allow us to monitor the evolution of antibiotic resistance. However, new legislation on general data protection regulations limits access to this data and this is a barrier to public health decision-making. In addition, these data could make it possible to set up registers of deaths due to antibiotic resistance necessary to avoid the fear caused by alarming published studies and reports.

Funding information: This work was supported by the French Government under the « Investissements d’avenir » (Investments for the Future) program managed by the Agence Nationale de la Recherche (ANR, fr: National Agency for Research), (reference: Méditerranée Infection 10-IAHU-03). This work was supported by Région Provence Alpes Côte d’Azur and European funding FEDER PRIM1.

Acknowledgment:

Transparency declaration: The authors declare that they have no competing interests.

408 **References**

- 409 [1] Aminov R. History of antimicrobial drug discovery: Major classes and health impact.
410 *Biochem Pharmacol* 2017;133:4–19. doi:10.1016/j.bcp.2016.10.001.
- 411 [2] Lewis K. Platforms for antibiotic discovery. *Nat Rev Drug Discov* 2013;12:371–87.
412 doi:10.1038/nrd3975.
- 413 [3] Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, et al.
414 Access to effective antimicrobials: a worldwide challenge. *Lancet* (London, England)
415 2016;387:168–75. doi:10.1016/S0140-6736(15)00474-2.
- 416 [4] GBD 2016 Causes of Death Collaborators*. Global, regional, and national age-sex
417 specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the
418 Global Burden of Disease Study 2016. *Lancet* 2017;390:1151–210.
419 doi:10.1016/S0140-6736(17)32152-9.
- 420 [5] Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global
421 increase and geographic convergence in antibiotic consumption between 2000 and
422 2015. *Proc Natl Acad Sci* 2018;201717295. doi:10.1073/pnas.1717295115.
- 423 [6] Abat C, Gautret P, Raoult D. Benefits of antibiotics burden in low-income countries.
424 *Proc Natl Acad Sci* 2018;115:E8109–10. doi:10.1073/pnas.1809354115.
- 425 [7] Rolain J-M, Abat C, Jimeno M-T, Fournier P-E, Raoult D. Do we need new
426 antibiotics? *Clin Microbiol Infect* 2016;22:408–15. doi:10.1016/j.cmi.2016.03.012.
- 427 [8] Abat C, Fournier P-E, Jimeno M-T, Rolain J-M, Raoult D. Extremely and pandrug-
428 resistant bacteria extra-deaths: myth or reality? *Eur J Clin Microbiol Infect Dis* 2018;1–
429 11. doi:10.1007/s10096-018-3300-0.
- 430 [9] Olesen SW, Barnett ML, MacFadden DR, Brownstein JS, Hernández-Díaz S, Lipsitch
431 M, et al. The distribution of antibiotic use and its association with antibiotic resistance.
432 *Elife* 2018;7. doi:10.7554/eLife.39435.
- 433 [10] Abat C, Rolain JM, Dubourg G, Fournier PE, Chaudet H, Raoult D. Evaluating the
434 Clinical Burden and Mortality Attributable to Antibiotic Resistance: The Disparity of
435 Empirical Data and Simple Model Estimations. *Clin Infect Dis* 2017;65:S58–63.
436 doi:10.1093/cid/cix346.
- 437 [11] O ’neill J. TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY: FINAL
438 REPORT AND RECOMMENDATIONS THE REVIEW ON ANTIMICROBIAL
439 RESISTANCE 2016.
- 440 [12] ECDC. The bacterial challenge : time to react. vol. 6 July 201. 2009. doi:10.2900/2518.
- 441 [13] CDC. Antibiotic resistance threats in the United States, 2013. *Current* 2013;114.
442 doi:CS239559-B.
- 443 [14] Colomb-Cotin M, Lacoste J, Coignard B, Vaux S. Morbidité et mortalité des
444 infections à bactéries multi-résistantes aux antibiotiques en France en 2012. *Inst Veill*
445 *Sanit* 2015;24.
- 446 [15] Abat C, Raoult D, Rolain JM. Are we living in an antibiotic resistance nightmare? *Clin*
447 *Microbiol Infect* 2018. doi:10.1016/j.cmi.2018.01.004.
- 448 [16] de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 Million People Die a Year due to
449 Antimicrobial Resistance by 2050? *PLoS Med* 2016;13.
450 doi:10.1371/journal.pmed.1002184.
- 451 [17] Abat C, Chaudet H, Colson P, Rolain JM, Raoult D. Real-time microbiology laboratory
452 surveillance system to detect abnormal events and emerging infections, Marseille,
453 France. *Emerg Infect Dis* 2015;21:1302–10. doi:10.3201/eid2108.141419.
- 454 [18] Dunne EF, Fey PD, Kludt P, Reporter R, Mostashari F, Shillam P, et al. Emergence of
455 domestically acquired ceftriaxone-resistant *Salmonella* infections associated with
456 AmpC beta-lactamase. *JAMA* 2000;284:3151–6. doi:10.1001/jama.284.24.3151.

- [19] Altorf-van der Kuil W, Schoffelen AF, de Greeff SC, Thijsen SFT, Alblas HJ, Notermans DW, et al. National laboratory-based surveillance system for antimicrobial resistance: a successful tool to support the control of antimicrobial resistance in the Netherlands. *Eurosurveillance* 2017;22. doi:10.2807/1560-7917.ES.2017.22.46.17-00062.
- [20] Baron S, Hadjadj L, Rolain JM, Olaitan AO. Molecular mechanisms of polymyxin resistance: knowns and unknowns. *Int J Antimicrob Agents* 2016;48:583–91. doi:10.1016/j.ijantimicag.2016.06.023.
- [21] Voss A, Loeffen F, Bakker J, Klaassen C, Wulf M. Methicillin-resistant *Staphylococcus aureus* in pig farming. *Emerg Infect Dis*. 2005 Dec. <http://dx.doi.org/10.3201/eid1112.050428>
- [22] Dyar OJ, Yin J, Ding L, Wikander K, Zhang T, Sun C, et al. Antibiotic use in people and pigs: a One Health survey of rural residents' knowledge, attitudes and practices in Shandong province, China. *J Antimicrob Chemother* 2018. doi:10.1093/jac/dky240.
- [23] Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, et al. Surveillance for control of antimicrobial resistance. *Lancet Infect Dis* 2018;18:e99–106. doi:10.1016/S1473-3099(17)30485-1.
- [24] Ashley EA, Recht J, Chua A, Dance D, Dhorda M, Thomas N V, et al. An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. *J Antimicrob Chemother* 2018. doi:10.1093/jac/dky026.
- [25] Kawanishi M, Abo H, Ozawa M, Uchiyama M, Shirakawa T, Suzuki S, et al. Prevalence of colistin resistance gene *mcr-1* and absence of *mcr-2* in *Escherichia coli* isolated from healthy food-producing animals in Japan. *Antimicrob Agents Chemother* 2017;61. doi:10.1128/AAC.02057-16.
- [26] Le Page S, Dubourg G, Baron SA, Rolain J-M, Raoult D. No global increase in resistance to antibiotics: a snapshot of resistance from 2001 to 2016 in Marseille, France. *Eur J Clin Microbiol Infect Dis* 2019;38:395–407. doi:10.1007/s10096-018-3439-8.
- [27] Ecdc. Surveillance of antimicrobial resistance in Europe 2017. doi:10.2900/230516.
- [28] Hombach M, Wolfensberger A, Kuster SP, Böttger EC. Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of gram-negative rods. *J Clin Microbiol* 2013;51:2385–7. doi:10.1128/JCM.00921-13.
- [29] Ebrahim M, Gravel D, Thabet C, Abdesselam K, Paramalingam S, Hyson C. Antimicrobial use and antimicrobial resistance trends in Canada: 2014. *Can Commun Dis Rep* 2016;42:227–31.
- [30] de Kraker MEA, Jarlier V, Monen JCM, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: Trends from the European antimicrobial resistance surveillance system. *Clin Microbiol Infect* 2013. doi:10.1111/1469-0691.12028.
- [31] Ironmonger D, Edeghere O, Bains A, Loy R, Woodford N, Hawkey PM. Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years. *J Antimicrob Chemother* 2014. doi:10.1093/jac/dkv043.
- [32] Hammerum AM, Heuer OE, Emborg H-D, Bagger-Skjøt L, Jensen VF, Rogues A-M, et al. Danish integrated antimicrobial resistance monitoring and research program. *Emerg Infect Dis* 2007. doi:10.3201/eid1311.070421.
- [33] Cimmino T, Le Page S, Raoult D, Rolain JM. Contemporary challenges and opportunities in the diagnosis and outbreak detection of multidrug-resistant infectious disease. *Expert Rev Mol Diagn* 2016. doi:10.1080/14737159.2016.1244005.

- [34] Aanensen DM, Feil EJ, Holden MTG, Dordel J, Yeats CA, Fedosejev A, et al. Whole-genome sequencing for routine pathogen surveillance in public health: A population snapshot of invasive *Staphylococcus aureus* in Europe. *MBio* 2016. doi:10.1128/mBio.00444-16.
- [35] Bradley P, Gordon NC, Walker TM, Dunn L, Heys S, Huang B, et al. Rapid antibiotic-resistance predictions from genome sequence data for *Staphylococcus aureus* and *Mycobacterium tuberculosis*. *Nat Commun* 2015. doi:10.1038/ncomms10063.
- [36] Stoesser N, Batty EM, Eyre DW, Morgan M, Wyllie DH, Del Ojo Elias C, et al. Predicting antimicrobial susceptibilities for *Escherichia coli* and *Klebsiella pneumoniae* isolates using whole genomic sequence data. *J Antimicrob Chemother* 2013. doi:10.1093/jac/dkt180.
- [37] McDermott PF, Tyson GH, Kabera C, Chen Y, Li C, Folster JP, et al. Whole-genome sequencing for detecting antimicrobial resistance in nontyphoidal *Salmonella*. *Antimicrob Agents Chemother* 2016. doi:10.1128/AAC.01030-16.
- [38] Walker TM, Kohl TA, Omar S V., Hedge J, Del Ojo Elias C, Bradley P, et al. Whole-genome sequencing for prediction of *Mycobacterium tuberculosis* drug susceptibility and resistance: A retrospective cohort study. *Lancet Infect Dis* 2015. doi:10.1016/S1473-3099(15)00062-6.
- [39] Schürch AC, van Schaik W. Challenges and opportunities for whole-genome sequencing–based surveillance of antibiotic resistance. *Ann N Y Acad Sci* 2017. doi:10.1111/nyas.13310.
- [40] Queenan K, Häsler B, Rushton J. A One Health approach to antimicrobial resistance surveillance: is there a business case for it? *Int J Antimicrob Agents* 2016. doi:10.1016/j.ijantimicag.2016.06.014.
- [41] Founou LL, Founou RC, Essack SY. Antibiotic resistance in the food chain: A developing country-perspective. *Front Microbiol* 2016;7. doi:10.3389/fmicb.2016.01881.
- [42] Sharma C, Rokana N, Chandra M, Singh BP, Gulhane RD, Gill JPS, et al. Antimicrobial Resistance: Its Surveillance, Impact, and Alternative Management Strategies in Dairy Animals. *Front Vet Sci* 2018;4. doi:10.3389/fvets.2017.00237.
- [43] Zinsstag J, Schelling E, Waltner-Toews D, Tanner M. From “one medicine” to “one health” and systemic approaches to health and well-being. *Prev Vet Med* 2011. doi:10.1016/j.prevetmed.2010.07.003.
- [44] PLAN D’ ACTION MONDIAL POUR COMBATTRE LA RÉSISTANCE AUX ANTIMICROBIENS. n.d.
- [45] Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant *Staphylococcus aureus* (MRSA). *Proc Natl Acad Sci U S A* 2002;99:7687–92. doi:10.1073/pnas.122108599.
- [46] Lau SH, Kaufmann ME, Livermore DM, Woodford N, Willshaw GA, Cheasty T, et al. UK epidemic *Escherichia coli* strains A-E, with CTX-M-15 β -lactamase, all belong to the international O25:H4-ST131 clone. *J Antimicrob Chemother* 2008;62:1241–4. doi:10.1093/jac/dkn380.
- [47] Viñas MR, Tuduri E, Galar A, Yih K, Pichel M, Stelling J, et al. Laboratory-Based Prospective Surveillance for Community Outbreaks of *Shigella* spp. in Argentina. *PLoS Negl Trop Dis* 2013. doi:10.1371/journal.pntd.0002521.
- [48] Stelling J, Yih WK, Galas M, Kulldorff M, Pichel M, Terragno R, et al. Automated use of WHONET and SaTScan to detect outbreaks of *Shigella* spp. using antimicrobial resistance phenotypes. *Epidemiol Infect* 2010. doi:10.1017/S0950268809990884.
- [49] Rossi A, Tokumoto M, Galas M, Soloaga R, Corso A. [Monitoring antibiotic resistance in Argentina. The WHONET program, 1995-1996]. *Pan Am J Public Heal* 1999.

- [50] Turnidge JD, Meleady KT. Antimicrobial Use and Resistance in Australia (AURA) surveillance system: coordinating national data on antimicrobial use and resistance for Australia. *Aust Heal Rev* 2018;42:272. doi:10.1071/AH16238.
- [51] Published by the Australian Commission on Safety and Quality in Health Care. n.d.
- [52] Nesbitt A, Ravel A, Murray R, McCormick R, Savelli C, Finley R, et al. Integrated surveillance and potential sources of *Salmonella* Enteritidis in human cases in Canada from 2003 to 2009. *Epidemiol Infect* 2012. doi:10.1017/S0950268811002548.
- [53] Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. *Clin Microbiol Infect* 2016. doi:10.1016/j.cmi.2016.01.001.
- [54] Guo H, Qin J, Xiang J. Surveillance for and susceptibility of *Acinetobacter baumannii* in a large hospital and burn center in Shanghai, China, 2007-2013. *Am J Infect Control* 2016. doi:10.1016/j.ajic.2016.06.014.
- [55] Xiao YH, Giske CG, Wei ZQ, Shen P, Heddini A, Li LJ. Epidemiology and characteristics of antimicrobial resistance in China. *Drug Resist Updat* 2011. doi:10.1016/j.drug.2011.07.001.
- [56] Acar JF, Moulin G. Integrating animal health surveillance and food safety: the issue of antimicrobial resistance. *Rev Sci Tech* 2013.
- [57] Carbonne A, Arnaud I, Maugat S, Marty N, Dumartin C, Bertrand X, et al. National multidrug-resistant bacteria (MDRB) surveillance in France through the RAISIN network: a 9 year experience. *J Antimicrob Chemother* 2013;68:954–9. doi:10.1093/jac/dks464.
- [58] Abat C, Raoult D, Rolain JM. Decreasing level of resistance in invasive *Klebsiella pneumoniae* strains isolated in Marseille, January 2012–July 2015. *Springerplus* 2016. doi:10.1186/s40064-016-2296-0.
- [59] Colson P, Rolain JM, Abat C, Charrel R, Fournier PE, Raoult D. EPIMIC: A simple homemade computer program for real-time epidemiological surveillance and alert based on microbiological data. *PLoS One* 2015;10. doi:10.1371/journal.pone.0144178.
- [60] Benoit SR, Lopez B, Arvelo W, Henao O, Parsons MB, Reyes L, et al. Burden of laboratory-confirmed *Campylobacter* infections in Guatemala 2008-2012: Results from a facility-based surveillance system. *J Epidemiol Glob Health* 2014. doi:10.1016/j.jegh.2013.10.001.
- [61] Gastmeier P, Schwab F, Behnke M, Geffers C. Decreasing healthcare-associated infections (HAI) is an efficient method to decrease healthcare-associated Methicillin-resistant *S.aureus* (MRSA) infections Antimicrobial resistance data from the German national nosocomial surveillance system KISS. *Antimicrob Resist Infect Control* 2012. doi:10.1186/2047-2994-1-3.
- [62] Meyer E, Jonas D, Schwab F, Rueden H, Gastmeier P, Daschner FD. Design of a surveillance system of antibiotic use and bacterial resistance in German intensive care units (SARI). *Infection* 2003. doi:10.1007/s15010-003-3201-7.
- [63] Meyer E, Gastmeier P, Deja M, Schwab F. Antibiotic consumption and resistance: Data from Europe and Germany. *Int J Med Microbiol* 2013. doi:10.1016/j.ijmm.2013.04.004.
- [64] Schweickert B, Noll I, Feig M, Claus H, Krause G, Velasco E, et al. MRSA-surveillance in Germany: Data from the Antibiotic Resistance Surveillance System (ARS) and the mandatory surveillance of MRSA in blood. *Eur J Clin Microbiol Infect Dis* 2012. doi:10.1007/s10096-011-1511-8.
- [65] Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P. Dramatic increase of third-generation cephalosporin-resistant *E. coli* in German intensive care units: Secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. *Crit Care* 2010.

- doi:10.1186/cc9062.
- [66] Falagas ME, Mourtzoukou EG, Polemis M, Vatopoulos AC, Resistance GS for S of A. Trends in antimicrobial resistance of *Acinetobacter baumannii* clinical isolates from hospitalised patients in Greece and treatment implications. *Clin Microbiol Infect* 2007. doi:10.1111/j.1469-0691.2007.01761.x.
- [67] Masoumi-Asl H, Gouya MM, Rahbar M, Sabourian R. The epidemiology and antimicrobial resistance of cholera cases in Iran during 2013. *Iran J Microbiol* 2016.
- [68] Martinelli D, Fortunato F, Prato R. Estimates of the burden of meningococcal disease in Italy: implications for prevention and control. *J Prev Med Hyg* 2015;56:E112-5.
- [69] Sabbatucci M, Dionisi AM, Pezzotti P, Lucarelli C, Barco L, Mancin M, et al. Molecular and epidemiologic analysis of reemergent salmonella enterica serovar Napoli, Italy, 2011–2015. *Emerg Infect Dis* 2018. doi:10.3201/eid2403.171178.
- [70] Suka M, Yoshida K, Takezawa J. Epidemiological approach to nosocomial infection surveillance data: The Japanese Nosocomial Infection Surveillance System. *Environ Health Prev Med* 2008. doi:10.1007/s12199-007-0004-y.
- [71] Makita K, Goto M, Ozawa M, Kawanishi M, Koike R, Asai T, et al. Multivariable Analysis of the Association Between Antimicrobial Use and Antimicrobial Resistance in *Escherichia coli* Isolated from Apparently Healthy Pigs in Japan. *Microb Drug Resist* 2016;22:28–39. doi:10.1089/mdr.2014.0311.
- [72] Abat C, Chaudet H, Rolain JM, Colson P, Raoult D. Traditional and syndromic surveillance of infectious diseases and pathogens. *Int J Infect Dis* 2016;48:22–8. doi:10.1016/j.ijid.2016.04.021.
- [73] MacDonald E, Vestrheim DF, White RA, Kongsmo K, Lange H, Aase A, et al. Are the current notification criteria for Lyme borreliosis in Norway suitable? Results of an evaluation of Lyme borreliosis surveillance in Norway, 1995-2013. *BMC Public Health* 2016. doi:10.1186/s12889-016-3346-9.
- [74] Mori T. Nationwide drug resistance survey of tuberculosis in the Philippines. *Int J Tuberc Lung Dis* 2009.
- [75] Perovic O, Singh-Moodley A, Duse A, Bamford C, Elliott G, Swe-Han KS, et al. National sentinel site surveillance for antimicrobial resistance in *Klebsiella pneumoniae* isolates in South Africa, 2010 - 2012. *S Afr Med J* 2014. doi:10.7196/SAMJ.7617.
- [76] Kim D, Ahn JY, Lee CH, Jang SJ, Lee H, Yong D, et al. Increasing resistance to extended-spectrum cephalosporins, fluoroquinolone, and carbapenem in gram-negative bacilli and the emergence of carbapenem non-susceptibility in *klebsiella pneumoniae*: Analysis of Korean Antimicrobial Resistance Monitoring System . *Ann Lab Med* 2017. doi:10.3343/alm.2017.37.3.231.
- [77] Lee SJ, Lee DS, Choe HS, Shim BS, Kim CS, Kim ME, et al. Antimicrobial resistance in community-acquired urinary tract infections: Results from the Korean Antimicrobial Resistance Monitoring System. *J Infect Chemother* 2011. doi:10.1007/s10156-010-0178-x.
- [78] Shibayama K, Lee H, Kim S. Comparison of Antibiotic Resistance Rate of Medically Important Microorganisms between Japan and Korea. *Ann Clin Microbiol* 2015;18:111. doi:10.5145/ACM.2015.18.4.111.
- [79] Jansson DS, Nilsson O, Lindblad J, Greko C, Bengtsson B. Inter-batch contamination and potential sources of vancomycin-resistant *Enterococcus faecium* on broiler farms. *Br Poult Sci* 2012. doi:10.1080/00071668.2012.750715.
- [80] Buetti N, Atkinson A, Marschall J, Kronenberg A. Incidence of bloodstream infections: A nationwide surveillance of acute care hospitals in Switzerland 2008-2014. *BMJ Open* 2017. doi:10.1136/bmjopen-2016-013665.

- [81] Kronenberg A, Hilty M, Endimiani A, Muhlemann K. Temporal trends of extended-spectrum cephalosporin-resistant *Escherichia coli* and *Klebsiella pneumoniae* isolates in in- and outpatients in Switzerland, 2004 to 2011. *Euro Surveill* 2013;18.
- [82] Dejsirilert S, Tiengrim S, Sawanpanyalert P, Aswapokee N, Malathum K. Antimicrobial resistance of *Acinetobacter baumannii*: six years of National Antimicrobial Resistance Surveillance Thailand (NARST) surveillance. *J Med Assoc Thai* 2009.
- [83] Kuzdan C, Soysal A, Çulha G, Altinkanat G, Söyletir G, Bakir M. Three-year study of health care-associated infections in a Turkish pediatric ward. *J Infect Dev Ctries* 2014. doi:10.3855/jidc.3931.
- [84] Tukenmez Tigen E, Dogru A, Koltka EN, Unlu C, Gura M. Device-associated nosocomial infection rates and distribution of antimicrobial resistance in a medical-surgical intensive care unit in Turkey. *Jpn J Infect Dis* 2014;67:5–8.
- [85] Johnson AP. Surveillance of antibiotic resistance. *Philos Trans R Soc Lond B Biol Sci* 2015;370:20140080. doi:10.1098/rstb.2014.0080.
- [86] Johnson AP, Davies J, Guy R, Abernethy J, Sheridan E, Pearson A, et al. Mandatory surveillance of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteraemia in England: The first 10 years. *J Antimicrob Chemother* 2012. doi:10.1093/jac/dkr561.
- [87] Bou-Antoun S, Davies J, Guy R, Johnson AP, Sheridan EA, Hope RJ. Descriptive epidemiology of *Escherichia coli* bacteraemia in England, april 2012 to march 2014. *Eurosurveillance* 2016. doi:10.2807/1560-7917.ES.2016.21.35.30329.
- [88] Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A, et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: The BSAC bacteraemia resistance surveillance programme. *J Antimicrob Chemother* 2004. doi:10.1093/jac/dkh232.
- [89] Borriello SP, Broadfoot F, Healey K, Brown S, Vidal A. Veterinary Antibiotic Resistance and Sales Surveillance Report. Uk-Varss 2016.
- [90] Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring antibiotic resistance in ocular microorganisms: Results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. *Am J Ophthalmol* 2011. doi:10.1016/j.ajo.2011.03.010.
- [91] Smith SE, Pratt R, Trieu L, Barry PM, Thai DT, Ahuja SD, et al. Epidemiology of Pediatric Multidrug-Resistant Tuberculosis in the United States, 1993–2014. *Clin Infect Dis* 2017;65:1437–43. doi:10.1093/cid/cix561.
- [92] Geissler AL, Bustos Carrillo F, Swanson K, Patrick ME, Fullerton KE, Bennett C, et al. Increasing *Campylobacter* Infections, Outbreaks, and Antimicrobial Resistance in the United States, 2004-2012. *Clin Infect Dis* 2017. doi:10.1093/cid/cix624.
- [93] Karp BE, Tate H, Plumblee JR, Dessai U, Whichard JM, Thacker EL, et al. National Antimicrobial Resistance Monitoring System: Two Decades of Advancing Public Health Through Integrated Surveillance of Antimicrobial Resistance. *Foodborne Pathog Dis* 2017. doi:10.1089/fpd.2017.2283.
- [94] Brown AC, Grass JE, Richardson LC, Nisler AL, Bicknese AS, Gould LH. Antimicrobial resistance in *Salmonella* that caused foodborne disease outbreaks: United States, 2003-2012. *Epidemiol Infect* 2017. doi:10.1017/S0950268816002867.
- [95] Kirkcaldy RD, Harvey A, Papp JR, del Rio C, Soge OO, Holmes KK, et al. *Neisseria gonorrhoeae* Antimicrobial Susceptibility Surveillance — The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014. *MMWR Surveill Summ* 2016. doi:10.15585/mmwr.ss6507a1.
- [96] Tveit AH, Bruce MG, Bruden DL, Morris J, Reasonover A, Hurlburt DA, et al. Alaska sentinel surveillance study of *Helicobacter pylori* isolates from Alaska native persons

- from 2000 to 2008. *J Clin Microbiol* 2011. doi:10.1128/JCM.01067-11.
- [97] Dauner DG, Roberts DF, Kotchmar GS. Statewide sentinel surveillance for antibiotic nonsusceptibility among *Streptococcus pneumoniae* isolates in South Carolina, 2003-2004. *South Med J* 2007. doi:10.1097/01.smj.0000232968.56740.e1.
- [98] Latif AS, Gwanzura L, Machiha A, Ndowa F, Tarupiwa A, Gudza-Mugabe M, et al. Antimicrobial susceptibility in *Neisseria gonorrhoeae* isolates from five sentinel surveillance sites in Zimbabwe, 2015-2016. *Sex Transm Infect* 2018. doi:10.1136/sextrans-2016-053090.
- [99] Borg MA, Cookson BD, Rasslan O, Gür D, Ben Redjeb S, Benbachir M, et al. Correlation between meticillin-resistant *Staphylococcus aureus* prevalence and infection control initiatives within southern and eastern Mediterranean hospitals. *J Hosp Infect* 2009. doi:10.1016/j.jhin.2008.09.007.
- [100] Borg MA, Cookson BD, Zarb P, Scicluna EA. Antibiotic resistance surveillance and control in the Mediterranean region: Report of the ARMed consensus conference. *J Infect Dev Ctries* 2009. doi:10.3855/jidc.210.
- [101] Weston EJ, Wi T, Papp J. Surveillance for antimicrobial drug-resistant *Neisseria gonorrhoeae* through the enhanced gonococcal antimicrobial surveillance program. *Emerg Infect Dis* 2017. doi:10.3201/eid2313.170443.
- [102] Cole MJ, Unemo M, Hoffmann S, Chisholm SA, Ison CA, Laar MJ van de. The European gonococcal antimicrobial surveillance programme, 2009. *Eurosurveillance* 2011;16:19995. doi:10.2807/ese.16.42.19995-en.
- [103] Spiteri G, Cole M, Unemo M, Hoffmann S, Ison C, van de Laar M. The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)—a sentinel approach in the European Union (EU)/European Economic Area (EEA). *Sex Transm Infect* 2013;89:iv16–8. doi:10.1136/sextrans-2013-051117.
- [104] Versporten A, Sharland M, Bielicki J, Drapier N, Vankerckhoven V, Goossens H. The Antibiotic Resistance and Prescribing in European Children Project: A Neonatal and Pediatric Antimicrobial Web-based Point Prevalence Survey in 73 Hospitals Worldwide. *Pediatr Infect Dis J* 2013. doi:10.1097/INF.0b013e318286c612.
- [105] Bruyndonckx R, Hens N, Aerts M, Goossens H, Abrahantes JC, Coenen S. Exploring the association between resistance and outpatient antibiotic use expressed as DDDs or packages. *J Antimicrob Chemother* 2014. doi:10.1093/jac/dku525.
- [106] de Kraker MEA, Davey PG, Grundmann H. Mortality and hospital stay associated with resistant *Staphylococcus aureus* and *Escherichia coli* bacteremia: Estimating the burden of antibiotic resistance in Europe. *PLoS Med* 2011. doi:10.1371/journal.pmed.1001104.
- [107] Tornimbene B, Eremin S, Escher M, Griskeviciene J, Manglani S, Pessoa-Silva CL. WHO Global Antimicrobial Resistance Surveillance System early implementation 2016-17. *Lancet Infect Dis* 2018. doi:10.1016/S1473-3099(18)30060-4.
- [108] Hu, F., Guo, Y., Y. et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. *Eur J Clin Microbiol Infec Dis* 2019. doi: <https://doi.org/10.1007/s10096-019-03673-1>.

Figures and Tables

Figures: 2

Figure 1. Flowchart of the selection of the studies

Figure 2. Future Antibiotic Resistance Surveillance System

Tables: 2


Table 1: Summary of the different species and/or genera monitored by antibiotic resistance surveillance systems around the world.

Table 2 Prevalence and/or incidence of phenotypes monitored by the different antibiotic resistance surveillance systems

Supplementary data: 1

Table S1: Summary of different antibiotic resistance surveillance systems around the world


Figure 1. Flowchart of the selection of the studies



782 **Figure 2.** Future Antibiotic Resistance Surveillance System

783

784



785
786

Antibiotic resistance surveillance systems	Species and/or genera monitored																																					
	<i>Staphylococcus spp</i>	<i>Escherichia coli</i>	<i>Streptococcus spp</i>	<i>Pseudomonas spp</i>	<i>Klebsiella spp</i>	<i>Enterococcus spp</i>	<i>Salmonella spp</i>	<i>Acinetobacter spp</i>	<i>Haemophilus spp</i>	<i>Enterobacter spp</i>	<i>Campylobacter spp</i>	<i>Mycobacterium spp</i>	<i>Neisseria spp</i>	<i>Proteus spp</i>	<i>Shigella spp</i>	<i>Serratia spp</i>	<i>Moraxella spp</i>	<i>Vibrio cholerae</i>	<i>Morganella spp</i>	<i>Stenotrophomonas spp</i>	<i>Clostridium difficile</i>	<i>Citrobacter spp</i>	<i>Helicobacter spp</i>	<i>Brachyspira spp</i>	<i>Actinobacillus spp</i>	<i>Pasteurella spp</i>	<i>Mannheimia haemolytica</i>	<i>Yersinia spp</i>	<i>Aeromonas spp</i>	<i>Providencia spp</i>	<i>Corynebacterium spp</i>	<i>Burkholderia spp</i>	<i>Myroides spp</i>	<i>Comamonas spp</i>	<i>Bacillus spp</i>	<i>Alcaligenes spp</i>		
ISIS-AR																																						
LABBASE2																																						
ANRESIS																																						
CARSS																																						
CHINET																																						
MARSS																																						
KONIS																																						
GERMS-SA																																						
EARS-NET																																						
BSAC																																						
KISS																																						
SARI																																						
ARS																																						
NARST																																						
ARMED																																						
GSSAR																																						
DANMAP																																						
NORM																																						
ITAVARM																																						
FINRES-VET																																						
BMR-RAISIN																																						
EPIMIC																																						
ONERBA																																						

787 **Table 1:** Summary of the different species and/or genera monitored by antibiotic resistance surveillance systems around the world.

Antibiotic resistance surveillance systems	Species and/or genera monitored																																					
	<i>Staphylococcus spp</i>	<i>Escherichia coli</i>	<i>Streptococcus spp</i>	<i>Pseudomonas spp</i>	<i>Klebsiella spp</i>	<i>Enterococcus spp</i>	<i>Salmonella spp</i>	<i>Acinetobacter spp</i>	<i>Haemophilus spp</i>	<i>Enterobacter spp</i>	<i>Campylobacter spp</i>	<i>Mycobacterium spp</i>	<i>Neisseria spp</i>	<i>Proteus spp</i>	<i>Shigella spp</i>	<i>Serratia spp</i>	<i>Moraxella spp</i>	<i>Vibrio cholerea</i>	<i>Morganella spp</i>	<i>Stenotrophomonas spp</i>	<i>Clostridium difficile</i>	<i>Citrobacter spp</i>	<i>Helicobacter spp</i>	<i>Brachyspira spp</i>	<i>Actinobacillus spp</i>	<i>Pasteurella spp</i>	<i>Mannheimia haemolytica</i>	<i>Yersinia spp</i>	<i>Aeromonas spp</i>	<i>Providencia spp</i>	<i>Corynebacterium spp</i>	<i>Burkholderia spp</i>	<i>Myroides spp</i>	<i>Comamonas spp</i>	<i>Bacillus spp</i>	<i>Alcalignes spp</i>		
GLASS																																						
JANIS																																						
ARSP																																						
CARAIERT																																						
AURA																																						
VICNISS																																						
WHONET																																						
ARMOR																																						
AR-ISS																																						
CA-MRSA																																						
CNISP																																						
JVARM																																						
NARMS																																						
CIPARS																																						
KARMS																																						
MARAN																																						
ISKRA																																						
EURO-GASP																																						
MIB																																						
NTSS																																						

788

Antibiotic resistance surveillance systems	Species and/or genera monitored																																					
	<i>Staphylococcus spp</i>	<i>Escherichia coli</i>	<i>Streptococcus spp</i>	<i>Pseudomonas spp</i>	<i>Klebsiella spp</i>	<i>Enterococcus spp</i>	<i>Salmonella spp</i>	<i>Acinetobacter spp</i>	<i>Haemophilus spp</i>	<i>Enterobacter spp</i>	<i>Campylobacter spp</i>	<i>Mycobacterium spp</i>	<i>Neisseria spp</i>	<i>Proteus spp</i>	<i>Shigella spp</i>	<i>Serratia spp</i>	<i>Moraxella spp</i>	<i>Vibrio cholerea</i>	<i>Morganella spp</i>	<i>Stenotrophomonas spp</i>	<i>Clostridium difficile</i>	<i>Citrobacter spp</i>	<i>Helicobacter spp</i>	<i>Brachyspira spp</i>	<i>Actinobacillus spp</i>	<i>Pasteurella spp</i>	<i>Mannheimia haemolytica</i>	<i>Yersinia spp</i>	<i>Aeromonas spp</i>	<i>Providencia spp</i>	<i>Corynebacterium spp</i>	<i>Burkholderia spp</i>	<i>Myroides spp</i>	<i>Comamonas spp</i>	<i>Bacillus spp</i>	<i>Alcalignes spp</i>		
GISP																																						
BULSTAR																																						
FIRE																																						
ARMIN																																						
SNARS																																						
SVEBAR																																						

790

791 Green: the species or species monitored (we put the genus when we have several species of the same genus); Red: not monitored by the systems.

792

793 **ISIS-AR:** Infectious Diseases Surveillance Information System for Antimicrobial Resistance; **LabBase2:** Health Protection Agency's voluntary;794 **ANRESIS:** Swiss Antibiotic Resistance Surveillance database; **Euro-GASP:** European gonococcal antimicrobial surveillance programme;795 **NARMS:** National Antimicrobial Resistance Monitoring System; **CARSS:** Canadian Antimicrobial Resistance Surveillance System; **CHINET:**796 Surveillance system for bacterial epidemiology and resistance in China; **MARSS:** Marseille Antibiotic Resistance Surveillance System;797 **KONIS :** Korean Nosocomial Infections Surveillance System; **GERMS-SA:** Group for Enteric, Respiratory and Meningeal Surveillance in798 South Africa; **EARS-NET:** European Antimicrobial Resistance Surveillance Network; **BSAC:** Bacteraemia and Respiratory Resistance799 Surveillance System; **KISS:** German national nosocomial infection surveillance system; **SARI:** Surveillance of Antibiotic-usage and bacterial800 Resistance on Intensive Care Units; **ARS:** Antibiotic Resistance Surveillance System; **NARST:** Antimicrobial Resistance Surveillance Thailand;801 **ARMED:** Antibiotic Resistance Surveillance & Control in the Mediterranean Region; **GSSAR:** Greek System for the Surveillance of802 Antimicrobial Resistance; **DANMAP:** Danish Integrated Antimicrobial Resistance Monitoring and Research Programme; **ITAVARM:** Italian803 Veterinary Antimicrobial Resistance Monitoring; **FINRES-VET:** Finnish Veterinary Antimicrobial Resistance Monitoring and Consumption of

804 Antimicrobial Agents report; **NORM**:Norwegian Surveillance System for Antimicrobial Drug Resistance; **BMR-RAISIN**:Bactéries
 805 MultiRésistantes-Réseau d’alerte d’investigation et de surveillance des infections nosocomiales; **EPIMIC**: EPIdemiological Surveillance and
 806 Alert Based on MICrobiological Data; **ONERBA**:National Observatory of Bacterial Resistance Epidemiology; **ENTERNET**:Italian surveillance
 807 system for foodborne and waterborne diseases; **BulSTAR**:Bulgarian Surveillance Trackling Antimicrobial Resistance; **ISKRA**:Intersectoral
 808 Coordination Mechanism for the Control of Antimicrobial Resistance; **FIRE**:Finnish Study Group for Antimicrobial Resistance;
 809 **ARMIN**:Monotoring antibiotic resistance in Niedersachsen; **AR-ISS**:Surveillance of antibiotic resistance; **SNARS**:Slovak National
 810 Antimicrobial Resistance Surveillance Sytem; **Svebar**:Swedish surveillance of antimicrobial resistance; **CA-MRSA**:CA-MRSA surveillance
 811 system; **CAESAR**:Central Asian and Eastern European Surveillance of Antimicrobial Resistance; **GLASS**: Global antimicrobial resistance
 812 surveillance system; **CNISP**:Canadian Nosocomial Infection Surveillance Programm; **JANIS**:Japan Nosocomial Infections Surveillance;
 813 **ARSP**:Phillipine Antimicrobial Resistance Surveillance Programm; **JVARM**:Japanese Veterinary Antimicrobial Resistance Monitoring System;
 814 **RELAVRA** :Latin American Surveillance Network of Antimicrobial Resistance; **MIB**:Invasive bacterial disease; **CARAlert**:National Alert
 815 System for Critical Antimicrobial Resistances; **AURA**:Antimicrobial Use and Resistance in Australia; **NTSS**:National TB surveillance system;
 816 **CIPARS**:Canadian Integrated Program for Antimicrobial Resistance Surveillance; **GISP**:Gonococcal Isolate Surveillance Project ; **KO-**
 817 **GLASS**:Korean Antimicrobial Resistance Monitoring System; **VICNISS**:Victorian Healthcare Associated Infection Surveillance System;
 818 **WHONET-Argentina**:National Argentine network for monitoring antimicrobial resistance; **ARMOR**:Antibiotic Resistance Monitoring in
 819 Ocular micRorganisms; **MARAN**:Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands;
 820
 821 **NB: Only systems with at least one species and/or genus monitored have been represented in this table.**
 822

823
824

Table 2 Prevalence and/or incidence of phenotypes monitored by the different antibiotic resistance surveillance systems

Antibiotic Resistance Surveillance Systems	Year	MRSA (Prevalence and/or Incidence)	ESBL_ <i>E.</i> (Prevalence and/or Incidence))	ESBL_ <i>K. pneumoniae</i> (Prevalence and/or Incidence)	<i>E. coli</i> resistant to Carbapenem (Prevalence and/or Incidence)	<i>K. pneumoniae</i> resistant to carbapenem (Prevalence and/or Incidence)	<i>E. faecalis</i> resistant to vancomycin (Prevalence and/or Incidence)	<i>E. faecium</i> resistant to vancomycin (Prevalence and/or Incidence)	<i>S. aureus</i> resistant to vancomycin (Prevalence and/or Incidence)	<i>S. pneumoniae</i> resistant to vancomycin (Prevalence and/or Incidence)	<i>S. pneumoniae</i> resistant to penicillin (Prevalence and/or Incidence)
ISIS-AR	2017	55963 (2.0)	177230 (4.5)	27322 (7.6)	176884 (0)	27285(0,2)	26385(0.3)	5406(1.1)	53075(0)	3024(0)	5351(4.7)
ANRESIS	2016	18763(6.7)	NA	NA	82118(0.3)	13598(1.8)	9867(0.2)	2861(4.8)	20212(0.1)	NA	1896(3.0)
AURA	2017	18551(13.5)	12	7	0.5	0.5	10424(0.5)	2 511(52.36)	NA	NA	4262(3.7)
CARSS	2017	3.13/10000	NA	NA	NA	NA	0.43	NA	NA	0	1132(10)
DANMAP	2016	3550(62.2/1000)	NA	NA	51618(<1)	15652(<1)	692(0)	692(7.3)	NA	NA	714(6.2)
KOR-GLASS	2015	390(53)	NA	NA	1104 (0)	422(2.0)	NA	NA	NA	NA	NA
EARS-NET	2017	56606(10.9)	121674(12.4)	30192(25.7)	120175(0.1)	29892(6.1)	18520(0.93)	12282(11.8)	NA		15402(6.9)
WHONET-ARGENTINE	2016	3046(45)	2170(17)	1903(48)	2170(1)	1903(14)	590(2)	226(64)	3046(0)	NA	732(25)
BSAC	2017	478(0.4)	496(8.7)	186(14.5)	496(0.2)	186(1.1)	105(1.0)	127(27.6)	478(0)	220(0)	220(8.2)
SARI	2017	23	16.3	15.7	NA	1.6	13.3	NA	NA	NA	NA

Antibiotic Resistance Surveillance Systems	Year	MRSA (Prevalence and/or Incidence)	ESBL <i>E. coli</i> (Prevalence and/or Incidence)	ESBL <i>K. pneumoniae</i> (prevalence and/or Incidence)	<i>E. coli</i> resistant to Carbapenem (Prevalence and/or Incidence)	<i>K. pneumoniae</i> resistant to carbapenem (Prevalence and/ or Incidence)	<i>E. faecalis</i> resistant to vancomycin ((Prevalence and/ or Incidence)	<i>E. faecium</i> resistant to vancomycin ((Prevalence and/ or Incidence)	<i>S. aureus</i> resistant to vancomycin (Prevalence and/or Incidence)	<i>S. pneumoniae</i> resistant to vancomycin (Prevalence and/or Incidence)	<i>S. pneumoniae</i> resistant to penicillin (Prevalence and/ or Incidence)
NARST	2017	30.8	50	48	2.16	8,83	0.7	8.3	9.6	0.8	37.8
WHONET-GREECE	2017	1716(33,16)	4938(10.9)	2138(60.56)	NA	2612(54.9)	2284(10.7)	2284(10.7)	NA	NA	NA
MSIS	2017	2538(49/ 100000)	3561(8.8)	1484(9.7)	3561(0)	1484(0)	421(0.2)	162(1.2)	2604(0)	NA	976(6.8)
NORM	2017	2538(49/ 100000)	3561(8,8)	1484(9,7)	3561(0,0)	1484(0,0)	421(0,2)	162(1,2)	2604(0,0)	NA	976(6.8)
BMR-RAISIN	2016	5180(0.24/1000)	8811(0.41/1 000)	3805(0.18/1 000)	NA	NA	NA	NA	NA	NA	NA
ONERBA	2015	11345(18.0)	34462(6.2)	18,3	0,37	0,18	3317(0)	624(0)	11303(0.1)	16.9	65(16.9)
BulSTAR	2016	222(13.0)	205(40.0)	NA	205(0)	95(3.0)	107(0)	41(15)	NA	NA	35(23.0)
ISKRA	2016	3 958(14.0)	19339(7.0)	4823(34)	19303(0.0)	4802(1.0)	5457(0.0)	826(15)	NA	NA	2130(22.0)
FIRE	2012	35997(3.00)	125655(8.6)	13950(2.5)	3306(0)	557(0)	23431(0)	4484(0.26)	NA	NA	1890(1.5)
ARMIN	2017	39847(14.4)	107680(14.2)	15410(16.9)	93436(0)	16401(0.2)	30498(0.1)	438(8.2)	37521(0)	NA	2508(12.4)
SVBAR	2016	3032(1.9)	NA	NA	4245(0.1)	1136(0.11)	NA	NA	NA	NA	NA

Antibiotic Resistance Surveillance Systems	Year	MRSA (Prevalence and/or Incidence)	ESBL_ <i>E.</i> (Prevalence and/or Incidence)	ESBL_ <i>K. pneumoniae</i> (Prevalence and/or Incidence)	<i>E. coli</i> resistant to Carbapenem (Prevalence and/or Incidence)	<i>K. pneumoniae</i> resistant to carbapenem (Prevalence and/or Incidence)	<i>E. faecalis</i> resistant to vancomycin (Prevalence and/or Incidence)	<i>E. faecium</i> resistant to vancomycin (Prevalence and/or Incidence)	<i>S. aureus</i> resistant to vancomycin (Prevalence and/or Incidence)	<i>S. pneumoniae</i> resistant to vancomycin (Prevalence and/or Incidence)	<i>S. pneumoniae</i> resistant to penicillin (Prevalence and/or Incidence)
CAESAR	2016	4732(24.7)	NA	NA	9420(28.00)	4934(22.5)	2566(2.9)	2184(15.7)	4950(0.3)	31(0)	861(26.7)
CNISP	2016	2241(2.3/1000)	NA	NA	24(0.10/1000)	49(0.10/1000)	299(0,32/1000)	299(0,32/1000)	NA	NA	NA
JANIS	2016	177,768(6.48)	NA	NA	284,316(0,00)	143,813(0.5)	124,305(0)	49,618(1.47)	181,288(0)	134(0)	36100(2.06)
ARSP	2017	5882(57.0)	3488(41.0)	6239(41.0)	8194(5.00)	11409(11.0)	1447(2.0)	791(5.0)	4250(2.0)	NA	421(10.0)
LABBASE	2017	NA	NA	NA	40272(0.07)	4000(1.5)	NA	NA	NA	NA	NA

827

828

829 **ISIS-AR:** Infectious Diseases Surveillance Information System for Antimicrobial Resistance; **LabBase2:** Health Protection Agency's voluntary;

830 **ANRESIS:** Swiss Antibiotic Resistance Surveillance database; **NARMS:** National Antimicrobial Resistance Monitoring System;

831 **CARSS:** Canadian Antimicrobial Resistance Surveillance System; **EARS-NET:** European Antimicrobial Resistance Surveillance Network;

832 **BSAC:** Bacteremia and Respiratory Resistance Surveillance System; **SARI:** Surveillance of Antibiotic-usage and bacterial Resistance on

833 Intensive Care Units; **ARS:** Antibiotic Resistance Surveillance System; **NARST:** Antimicrobial Resistance Surveillance Thailand; **ARMED:**

834 Antibiotic Resistance Surveillance & Control in the Mediterranean Region; **DANMAP:** Danish Integrated Antimicrobial Resistance Monitoring

835 and Research Programme; **NORM:** Norwegian Surveillance System for Antimicrobial Drug Resistance; **BMR-RAISIN:** Bactéries

836 MultiRésistantes-Réseau d’alerte d’investigation et de surveillance des infections nosocomiales; **ONERBA:** National Observatory of Bacterial
837 Resistance Epidemiology; **BulSTAR:** Bulgarian Surveillance Tackling Antimicrobial Resistance; **ISKRA:** Intersectoral Coordination
838 Mechanism for the Control of Antimicrobial Resistance; **FIRE:** Finnish Study Group for Antimicrobial Resistance; **AR-ISS:** Surveillance of
839 antibiotic resistance; **SNARS:** Slovak National Antimicrobial Resistance Surveillance System; **Svebar:** Swedish surveillance of antimicrobial
840 resistance; **CA-MRSA:**CA-MRSA surveillance system; **CAESAR:** Central Asian and Eastern European Surveillance of Antimicrobial
841 Resistance; **GLASS:** Global antimicrobial resistance surveillance system; **CNISP:** Canadian Nosocomial Infection Surveillance Program;
842 **JANIS:** Japan Nosocomial Infections Surveillance; **ARSP:** Philippine Antimicrobial Resistance Surveillance Program; **AURA:** Antimicrobial
843 Use and Resistance in Australia; **NTSS:** National TB surveillance system; **CIPARS:** Canadian Integrated Program for Antimicrobial Resistance
844 Surveillance; **GISP:** Gonococcal Isolate Surveillance Project ; **KO-GLASS:** Korean Antimicrobial Resistance Monitoring System; **WHONET-**
845 **Argentina:** National Argentine network for monitoring antimicrobial resistance;

846

847

848

849

850

851

852

853

854